Nanomedicine gets personal

Companion nanoparticle imaging merges with drug delivery technologies toward personalized nanomedicine (Miller et al., this issue). Companion nanoparticle imaging merges with drug delivery technologies toward personalized nanomedicine (Miller et al., this issue).

[1]  Robert Langer,et al.  Preclinical Development and Clinical Translation of a PSMA-Targeted Docetaxel Nanoparticle with a Differentiated Pharmacological Profile , 2012, Science Translational Medicine.

[2]  W. Mark Saltzman,et al.  A holistic approach to targeting disease with polymeric nanoparticles , 2015, Nature Reviews Drug Discovery.

[3]  I. Kwon,et al.  Theranostic nanoparticles for future personalized medicine. , 2014, Journal of controlled release : official journal of the Controlled Release Society.

[4]  John A Butman,et al.  Validation of dynamic contrast-enhanced magnetic resonance imaging-derived vascular permeability measurements using quantitative autoradiography in the RG2 rat brain tumor model. , 2007, Neoplasia.

[5]  J. Kreuter,et al.  Drug delivery to the central nervous system by polymeric nanoparticles: what do we know? , 2014, Advanced drug delivery reviews.

[6]  R. Bindra,et al.  Advances in Radiation Therapy in Pediatric Neuro-oncology , 2016, Journal of child neurology.

[7]  H. Maeda,et al.  A new concept for macromolecular therapeutics in cancer chemotherapy: mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs. , 1986, Cancer research.

[8]  Christopher J. Cheng,et al.  Nanoparticle-based therapy in an in vivo microRNA-155 (miR-155)-dependent mouse model of lymphoma , 2012, Proceedings of the National Academy of Sciences.

[9]  Ashley M. Laughney,et al.  Predicting therapeutic nanomedicine efficacy using a companion magnetic resonance imaging nanoparticle , 2015, Science Translational Medicine.

[10]  V. Muzykantov,et al.  Multifunctional Nanoparticles: Cost Versus Benefit of Adding Targeting and Imaging Capabilities , 2012, Science.